Medicinal Cannabis and GLP-1 Drug Risks

This chapter addresses the Australian Health Practitioner Regulation Agency's scrutiny of medicinal cannabis prescribing and the implications of GLP-1 drugs related to patient safety and eye health. It highlights new research linking these diabetes medications to a higher risk of wet age-related macular degeneration, raising concerns about their long-term effects on vulnerable patients. The discussion also stresses the need for further research and guidelines to ensure safer prescribing practices.